Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted equity awards to five newly-hired non-executive employees on October 1, 2026, consisting of options to purchase 144,400 ordinary shares at $21.28 per share with a 10-year term. The inducement grants were approved by the Compensation Committee as material incentives for employment acceptance.

10/02/2026, 7:59 AM • GlobeNewswire

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics announced equity inducement grants to three newly-hired non-executive employees on September 1, 2026. The grants consist of options to purchase 135,400 ordinary shares at $28.18 per share with a 10-year term and standard 4-year vesting schedule. The awards were approved by the Compensation Committee as material inducements for employment.

09/03/2026, 8:00 AM • GlobeNewswire

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics announced the appointment of Jennifer Jarrett as President and Chief Executive Officer, granting her 500,000 RSUs and options to purchase 1.5 million shares. The company also granted equity awards to four non-executive employees as inducement for joining the biotechnology firm focused on treating blood disorders.

03/30/2026, 8:00 AM • GlobeNewswire

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Galecto Inc (NASDAQ: GLTO), a biopharmaceutical company focused on blood cancer therapeutics, successfully closed its underwritten public offering of 16,644,737 shares at $19.00 per share, generating gross proceeds of $316.3 million. The offering included the full exercise of underwriters' option to purchase additional shares.

02/12/2026, 4:01 PM • Benzinga

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto, Inc. (NASDAQ: GLTO) announced the pricing of an underwritten public offering of 14.47 million shares at $19.00 per share, expected to raise approximately $275 million in gross proceeds. The offering is expected to close on February 12, 2026. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers.

02/10/2026, 10:42 PM • GlobeNewswire

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Galecto's Board of Directors approved granting 312,535 non-qualified stock options to a new employee at an exercise price of $32.00, with a vesting schedule starting from the first anniversary of the grant date.

12/16/2025, 5:00 PM • GlobeNewswire

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Galecto Inc. acquired Damora Therapeutics, expanding its blood cancer pipeline and securing $284.9 million in funding through a private placement, with plans to advance multiple therapeutic programs targeting myeloproliferative neoplasms and acute myeloid leukemia.

11/10/2025, 11:47 AM • Benzinga

Galecto Announces Acquisition of Damora Therapeutics

Galecto acquired Damora Therapeutics, a biotechnology company developing therapies for myeloproliferative neoplasms, in a transaction accompanied by a $285 million private investment that positions the company to advance potentially breakthrough treatments for blood cancers.

11/10/2025, 7:00 AM • GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

09/25/2025, 5:06 PM • Benzinga